Key Points
- Insider sale: Director Alexander Schuth sold 17,218 shares on Jan. 6 at an average price of $16.50 for proceeds of about $284,097, reducing his stake by 5.74% to 282,828 shares (worth ~ $4.67M).
- Market and analyst context: DNLI opened at $17.07 (12‑month range $10.57–$24.34) with a market cap of ~$2.5B, and carries a consensus rating of Buy with an average price target of $32.77.
- Company focus: Denali is a clinical‑stage biopharma developing therapies for neurodegenerative diseases using a Blood–Brain Barrier Transport Vehicle platform, with lead programs including an oral LRRK2 inhibitor for Parkinson’s and an anti‑TREM2 antibody for Alzheimer’s.
Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) insider Alexander Schuth sold 17,218 shares of the business's stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $284,097.00. Following the completion of the transaction, the insider owned 282,828 shares of the company's stock, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Denali Therapeutics Trading Up 0.7%
NASDAQ:DNLI opened at $17.07 on Friday. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $24.34. The firm has a market cap of $2.50 billion, a PE ratio of -5.87 and a beta of 1.05. The company has a current ratio of 9.79, a quick ratio of 9.79 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average price of $17.34 and a 200 day moving average price of $15.64.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.74) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.02. During the same period last year, the company earned ($0.63) EPS. The firm's revenue was up .0% on a year-over-year basis. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on DNLI. JPMorgan Chase & Co. boosted their target price on shares of Denali Therapeutics from $24.00 to $26.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Denali Therapeutics in a report on Wednesday, October 8th. UBS Group started coverage on Denali Therapeutics in a research note on Wednesday. They set a "buy" rating for the company. BTIG Research reiterated a "buy" rating and issued a $32.00 price target on shares of Denali Therapeutics in a research note on Friday, December 5th. Finally, Morgan Stanley reissued an "overweight" rating and set a $40.00 price objective on shares of Denali Therapeutics in a report on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $32.77.
View Our Latest Analysis on DNLI
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics during the second quarter worth about $26,000. Johnson Financial Group Inc. purchased a new stake in shares of Denali Therapeutics during the third quarter worth approximately $29,000. State of Wyoming acquired a new stake in shares of Denali Therapeutics during the second quarter worth $29,000. Quarry LP purchased a new position in Denali Therapeutics in the 3rd quarter valued at $64,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Denali Therapeutics by 15.5% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,612 shares of the company's stock valued at $79,000 after buying an additional 753 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.
About Denali Therapeutics
(
Get Free Report)
Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company's research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali's approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.
Among Denali's lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson's disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer's patients.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
